Crossject Société Anonyme announced the signing of a US & Canada commercial agreement. Crossject and Eton Pharmaceuticals signed an agreement for ZENEO® Hydrocortisone in the US and Canada. Under the terms of this agreement, Eton will be responsible for all regulatory and commercial activities, including licensing, regulatory filing fees, distribution, and promotion.

The agreement covers the US and Canada, a high market potential geographic area. Crossject will be responsible for the management and expense of development, clinical, and manufacturing activities.